Whitechapel Australia is working with Microstara Research LLC to develop distribution and commercialisation agreements to cover the Australasian market for their patented products for relief in specific vascular and neurological disorders focusing on Parkinson’s Disease and Migraine.
Parkinson’s Disease is primarily caused by low and falling levels of the dopamine neurotransmitters or chemical messengers. A person with Parkinson’s has abnormally low dopamine levels. Dopamine-generating cells, known as dopaminergic neurons (types of nerve cells) in the substantia nigra part of the brain have died. Experts do not know why these cells die. However, the most effective agent for regenerating the dopamine receptors is nicotine. By administering a sublingual spray, Microstrada’s nicotine-based formula goes from the oral cavity into the blood stream and directly into the brain. Case studies have shown 85% efficacy in eliminating or reducing the teradyne dyskinesia (the shaking) and no long term tachyphylaxis. (Tachyphylaxis is a medical term describing an acute (sudden) decrease in the response to a drug after its administration.) The product must be taken continuously or the symptoms will return. Other meds such as Levadopa can be taken concurrently with no known side effects.
Microstrada’s migraine product differs from the competition in that the formulation attacks the triggers of almost all migraines, stress and neurological imbalances. The process includes New Combinations of Matter that release dopamine and serotonin, as well as a vascular restrictor which affect the cause of most migraines. The product has shown to be effective within three to 10 minutes of ingestion/oral cavity following the first onset of migraine symptoms.